LivaNova stock heads toward November results after raised guidance

Published on 10/05/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LivaNova stock posted USD 390.6 million in Q2 revenue on August 5, 2026. Management lifted 2026 revenue growth guidance to 8-9 percent and adjusted EPS to USD 4.30-4.40.

LIVN, GB00BYMT0J19, Illustration mit AI erstellt.

LivaNova (ISIN GB00BYMT0J19) closed at USD 75.07 on Nasdaq on October 2, 2026, up 0.50 percent from the previous close. The company entered the final weeks before its next report after raising its full-year outlook in its second-quarter release dated August 5, 2026.

Revenue reached USD 390.6 million

Business Wire reported that second-quarter revenue reached USD 390.6 million for the period ended June 30, 2026, up 10.8 percent on a reported basis and 9.8 percent on a constant-currency basis from the prior-year quarter. U.S. GAAP diluted earnings per share came to USD 1.93 for Q2 2026.

The earnings mix also showed operating leverage. Finance-statement data place Q2 2026 consolidated net income at USD 108.7 million and operating margin at 13.0 percent, while operating cash flow reached USD 66.6 million for the same quarter.

Guidance moves higher before November

Yahoo Finance reported that LivaNova raised its 2026 revenue growth outlook to 8-9 percent from 7-8 percent. Adjusted diluted EPS guidance also increased to USD 4.30-4.40, with the midpoint representing 11.5 percent growth.

The upgrade was not uniform across the cash outlook. Management lowered adjusted free cash flow guidance to USD 140-160 million while pointing to investment in innovation, information technology infrastructure and cardiopulmonary capacity expansion, according to the same earnings-call coverage from Yahoo Finance.

Consensus target stays above USD 84

MarketBeat lists a Moderate Buy consensus from 11 analysts, with six Buy ratings and five Hold ratings. Its average price target of USD 84.12 lies 12.1 percent above the October 2 closing price of USD 75.07.

The technical picture is more restrained: MarketBeat reported that the shares traded as low as USD 74.64 against a 50-day moving average of USD 79.30 on October 3, 2026. The contrast leaves the raised operating outlook competing with a share price below that short-term trend measure.

Next report is scheduled for November 4

LivaNova will announce third-quarter 2026 results on November 4, 2026, before its conference call, according to Business Wire. The upcoming release will test whether the 8-9 percent full-year revenue growth range remains supported by the company's Cardiopulmonary and Neuromodulation operations.

Stock remains below its 52-week high

LivaNova stock closed at USD 75.07 on Nasdaq on October 2, 2026. The price stood between the 52-week low of USD 48.82 and high of USD 85.76, while market capitalization was USD 4.1 billion and session volume was 528,517 shares.